Collins Helen Louise bought ELVN
February 12, 2026 · Form 4 insider transaction
Collins Helen Louise bought 150,000 shares of Enliven Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 5 days after the transaction.
Direction
Acquired (buy-side)
Shares
150,000
Price
$0.00
Total value
N/A
InsiderCollins Helen Louise
RoleOfficer, Director
SecurityStock Option (right to buy)
Transaction codeA: Grant or award
Transaction dateFebruary 12, 2026
Filing dateFebruary 17, 2026
Shares owned after150,000
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.